AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer
Although aldo-keto reductases (AKRs) have been widely studied in cancer, no study to date has examined the roles of AKR family 1 members B1 (AKR1B1) and B10 (AKR1B10) in a large group of ovarian cancer patients. AKR1B1 and AKR1B10 play a significant role in inflammation and the metabolism of differe...
Gespeichert in:
| Veröffentlicht in: | Cancers 2022-02, Vol.14 (3), p.809 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 809 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Hojnik, Marko Šuster, Nataša Kenda Smrkolj, Špela Sisinger, Damjan Grazio, Snježana Frković Verdenik, Ivan Rižner, Tea Lanišnik |
| description | Although aldo-keto reductases (AKRs) have been widely studied in cancer, no study to date has examined the roles of AKR family 1 members B1 (AKR1B1) and B10 (AKR1B10) in a large group of ovarian cancer patients. AKR1B1 and AKR1B10 play a significant role in inflammation and the metabolism of different chemotherapeutics as well as cell differentiation, proliferation, and apoptosis. Due to these functions, we examined the potential of AKR1B1 and AKR1B10 as tissue biomarkers. We assessed the immunohistochemical levels of AKR1B1 and AKR1B10 in tissue paraffin sections from 99 patients with high-grade serous ovarian cancer (HGSC) and compared these levels with clinicopathological characteristics, survival, and response to chemotherapy. A higher immunohistochemical AKR1B1 expression correlated with a better overall and disease-free survival of HGSC patients whereas AKR1B10 expression did not show any significant differences. A multivariant Cox analysis demonstrated that a high AKR1B1 expression was an important prognostic factor for both overall and disease-free survival. However, AKR1B1 and AKR1B10 were not associated with different responses to chemotherapy. Our data suggest that AKR1B1 is involved in the pathogenesis of HGSC and is a potential prognostic biomarker for this cancer. |
| doi_str_mv | 10.3390/cancers14030809 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8834204</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2629063277</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-8bc4345e6ca2f15275636ed68ca5ec2439e913d6c0af5e1541771d2250d811c73</originalsourceid><addsrcrecordid>eNpdkUtPAjEUhRujEYKs3ZkmbtyM9N2ZjQmggpEE42PdlE4HBmGK7QyJ_95BkCDd3Cb97uk5OQBcYnRLaYI6RhfG-oAZoihGyQloEiRJJETCTg_uDdAOYY7qQymWQp6DBuWYJ0iKJrjvPr_iHoY6QA1fvJsWLpS5gb3cLbX_tB66DA7z6SwaeJ1a-Ga9qwIcr7XPdQH7vxYuwFmmF8G2d7MFPh4f3vvDaDQePPW7o8gwgssonhhGGbfCaJJhTiQXVNhUxEZzawijiU0wTYVBOuMWc4alxCkhHKUxxkbSFrjb6q6qydKmxhal1wu18nnt9Vs5nav_L0U-U1O3VnFMGUGsFrjZCXj3VdlQqmUejF0sdGHrWIoIkiBBidz8dX2Ezl3lizrehpKcxJLhmupsKeNdCN5mezMYqU1J6qikeuPqMMOe_6uE_gB1lowS</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627528741</pqid></control><display><type>article</type><title>AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Hojnik, Marko ; Šuster, Nataša Kenda ; Smrkolj, Špela ; Sisinger, Damjan ; Grazio, Snježana Frković ; Verdenik, Ivan ; Rižner, Tea Lanišnik</creator><creatorcontrib>Hojnik, Marko ; Šuster, Nataša Kenda ; Smrkolj, Špela ; Sisinger, Damjan ; Grazio, Snježana Frković ; Verdenik, Ivan ; Rižner, Tea Lanišnik</creatorcontrib><description>Although aldo-keto reductases (AKRs) have been widely studied in cancer, no study to date has examined the roles of AKR family 1 members B1 (AKR1B1) and B10 (AKR1B10) in a large group of ovarian cancer patients. AKR1B1 and AKR1B10 play a significant role in inflammation and the metabolism of different chemotherapeutics as well as cell differentiation, proliferation, and apoptosis. Due to these functions, we examined the potential of AKR1B1 and AKR1B10 as tissue biomarkers. We assessed the immunohistochemical levels of AKR1B1 and AKR1B10 in tissue paraffin sections from 99 patients with high-grade serous ovarian cancer (HGSC) and compared these levels with clinicopathological characteristics, survival, and response to chemotherapy. A higher immunohistochemical AKR1B1 expression correlated with a better overall and disease-free survival of HGSC patients whereas AKR1B10 expression did not show any significant differences. A multivariant Cox analysis demonstrated that a high AKR1B1 expression was an important prognostic factor for both overall and disease-free survival. However, AKR1B1 and AKR1B10 were not associated with different responses to chemotherapy. Our data suggest that AKR1B1 is involved in the pathogenesis of HGSC and is a potential prognostic biomarker for this cancer.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14030809</identifier><identifier>PMID: 35159076</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Apoptosis ; Biomarkers ; Cell differentiation ; Chemotherapy ; Kinases ; Mutation ; Ovarian cancer ; Paraffin</subject><ispartof>Cancers, 2022-02, Vol.14 (3), p.809</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-8bc4345e6ca2f15275636ed68ca5ec2439e913d6c0af5e1541771d2250d811c73</citedby><cites>FETCH-LOGICAL-c421t-8bc4345e6ca2f15275636ed68ca5ec2439e913d6c0af5e1541771d2250d811c73</cites><orcidid>0000-0001-9698-2130 ; 0000-0001-6249-5799 ; 0000-0002-3453-4081</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834204/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834204/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35159076$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hojnik, Marko</creatorcontrib><creatorcontrib>Šuster, Nataša Kenda</creatorcontrib><creatorcontrib>Smrkolj, Špela</creatorcontrib><creatorcontrib>Sisinger, Damjan</creatorcontrib><creatorcontrib>Grazio, Snježana Frković</creatorcontrib><creatorcontrib>Verdenik, Ivan</creatorcontrib><creatorcontrib>Rižner, Tea Lanišnik</creatorcontrib><title>AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Although aldo-keto reductases (AKRs) have been widely studied in cancer, no study to date has examined the roles of AKR family 1 members B1 (AKR1B1) and B10 (AKR1B10) in a large group of ovarian cancer patients. AKR1B1 and AKR1B10 play a significant role in inflammation and the metabolism of different chemotherapeutics as well as cell differentiation, proliferation, and apoptosis. Due to these functions, we examined the potential of AKR1B1 and AKR1B10 as tissue biomarkers. We assessed the immunohistochemical levels of AKR1B1 and AKR1B10 in tissue paraffin sections from 99 patients with high-grade serous ovarian cancer (HGSC) and compared these levels with clinicopathological characteristics, survival, and response to chemotherapy. A higher immunohistochemical AKR1B1 expression correlated with a better overall and disease-free survival of HGSC patients whereas AKR1B10 expression did not show any significant differences. A multivariant Cox analysis demonstrated that a high AKR1B1 expression was an important prognostic factor for both overall and disease-free survival. However, AKR1B1 and AKR1B10 were not associated with different responses to chemotherapy. Our data suggest that AKR1B1 is involved in the pathogenesis of HGSC and is a potential prognostic biomarker for this cancer.</description><subject>Apoptosis</subject><subject>Biomarkers</subject><subject>Cell differentiation</subject><subject>Chemotherapy</subject><subject>Kinases</subject><subject>Mutation</subject><subject>Ovarian cancer</subject><subject>Paraffin</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkUtPAjEUhRujEYKs3ZkmbtyM9N2ZjQmggpEE42PdlE4HBmGK7QyJ_95BkCDd3Cb97uk5OQBcYnRLaYI6RhfG-oAZoihGyQloEiRJJETCTg_uDdAOYY7qQymWQp6DBuWYJ0iKJrjvPr_iHoY6QA1fvJsWLpS5gb3cLbX_tB66DA7z6SwaeJ1a-Ga9qwIcr7XPdQH7vxYuwFmmF8G2d7MFPh4f3vvDaDQePPW7o8gwgssonhhGGbfCaJJhTiQXVNhUxEZzawijiU0wTYVBOuMWc4alxCkhHKUxxkbSFrjb6q6qydKmxhal1wu18nnt9Vs5nav_L0U-U1O3VnFMGUGsFrjZCXj3VdlQqmUejF0sdGHrWIoIkiBBidz8dX2Ezl3lizrehpKcxJLhmupsKeNdCN5mezMYqU1J6qikeuPqMMOe_6uE_gB1lowS</recordid><startdate>20220205</startdate><enddate>20220205</enddate><creator>Hojnik, Marko</creator><creator>Šuster, Nataša Kenda</creator><creator>Smrkolj, Špela</creator><creator>Sisinger, Damjan</creator><creator>Grazio, Snježana Frković</creator><creator>Verdenik, Ivan</creator><creator>Rižner, Tea Lanišnik</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9698-2130</orcidid><orcidid>https://orcid.org/0000-0001-6249-5799</orcidid><orcidid>https://orcid.org/0000-0002-3453-4081</orcidid></search><sort><creationdate>20220205</creationdate><title>AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer</title><author>Hojnik, Marko ; Šuster, Nataša Kenda ; Smrkolj, Špela ; Sisinger, Damjan ; Grazio, Snježana Frković ; Verdenik, Ivan ; Rižner, Tea Lanišnik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-8bc4345e6ca2f15275636ed68ca5ec2439e913d6c0af5e1541771d2250d811c73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Apoptosis</topic><topic>Biomarkers</topic><topic>Cell differentiation</topic><topic>Chemotherapy</topic><topic>Kinases</topic><topic>Mutation</topic><topic>Ovarian cancer</topic><topic>Paraffin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hojnik, Marko</creatorcontrib><creatorcontrib>Šuster, Nataša Kenda</creatorcontrib><creatorcontrib>Smrkolj, Špela</creatorcontrib><creatorcontrib>Sisinger, Damjan</creatorcontrib><creatorcontrib>Grazio, Snježana Frković</creatorcontrib><creatorcontrib>Verdenik, Ivan</creatorcontrib><creatorcontrib>Rižner, Tea Lanišnik</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hojnik, Marko</au><au>Šuster, Nataša Kenda</au><au>Smrkolj, Špela</au><au>Sisinger, Damjan</au><au>Grazio, Snježana Frković</au><au>Verdenik, Ivan</au><au>Rižner, Tea Lanišnik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2022-02-05</date><risdate>2022</risdate><volume>14</volume><issue>3</issue><spage>809</spage><pages>809-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Although aldo-keto reductases (AKRs) have been widely studied in cancer, no study to date has examined the roles of AKR family 1 members B1 (AKR1B1) and B10 (AKR1B10) in a large group of ovarian cancer patients. AKR1B1 and AKR1B10 play a significant role in inflammation and the metabolism of different chemotherapeutics as well as cell differentiation, proliferation, and apoptosis. Due to these functions, we examined the potential of AKR1B1 and AKR1B10 as tissue biomarkers. We assessed the immunohistochemical levels of AKR1B1 and AKR1B10 in tissue paraffin sections from 99 patients with high-grade serous ovarian cancer (HGSC) and compared these levels with clinicopathological characteristics, survival, and response to chemotherapy. A higher immunohistochemical AKR1B1 expression correlated with a better overall and disease-free survival of HGSC patients whereas AKR1B10 expression did not show any significant differences. A multivariant Cox analysis demonstrated that a high AKR1B1 expression was an important prognostic factor for both overall and disease-free survival. However, AKR1B1 and AKR1B10 were not associated with different responses to chemotherapy. Our data suggest that AKR1B1 is involved in the pathogenesis of HGSC and is a potential prognostic biomarker for this cancer.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35159076</pmid><doi>10.3390/cancers14030809</doi><orcidid>https://orcid.org/0000-0001-9698-2130</orcidid><orcidid>https://orcid.org/0000-0001-6249-5799</orcidid><orcidid>https://orcid.org/0000-0002-3453-4081</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-02, Vol.14 (3), p.809 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8834204 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Apoptosis Biomarkers Cell differentiation Chemotherapy Kinases Mutation Ovarian cancer Paraffin |
| title | AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T21%3A48%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AKR1B1%20as%20a%20Prognostic%20Biomarker%20of%20High-Grade%20Serous%20Ovarian%20Cancer&rft.jtitle=Cancers&rft.au=Hojnik,%20Marko&rft.date=2022-02-05&rft.volume=14&rft.issue=3&rft.spage=809&rft.pages=809-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14030809&rft_dat=%3Cproquest_pubme%3E2629063277%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627528741&rft_id=info:pmid/35159076&rfr_iscdi=true |